

In the Claims:

This version of the claims replaces all prior claims.

1. (Currently amended) A method of treating a patient requiring long-term therapy following hematopoietic cell transplantation having graft-versus-host disease or following organ allograft transplantation having host-versus-graft disease, the method comprising long term topical oral administration of beclomethasone dipropionate ~~a topically active corticosteroid~~ wherein treatment is directed to tissue selected from the group consisting of intestine and liver and further wherein the beclomethasone dipropionate ~~topically active corticosteroid~~ is initially administered at least 29 days post transplantation through 56 days post transplantation.

2. (Currently amended) The method of claim 1 wherein the beclomethasone dipropionate ~~topically active corticosteroid~~ is administered orally at a dosage of 4 mg per day to 12 mg per day.

3. (Previously presented) The method of claim 1 wherein the patient has tissue damage and the tissue is intestinal mucosa.

4. (Previously presented) The method of claim 1 wherein the patient has tissue damage and the tissue is small bile ducts in the liver.

5. (Previously presented) The method of claim 1 wherein the patient has tissue damage and the tissue damage is inflammation.
6. (Previously presented) The method of claim 1 wherein the patient has tissue damage and the tissue damage is destruction of the mucosa of the intestine.
7. (Currently amended) The method of claim 1 wherein the beclomethasone dipropionate ~~topically active corticosteroid~~ is administered orally from day 29 to day 56 following hematopoietic cell transplantation.
8. (Currently amended) The method of claim 1 wherein the beclomethasone dipropionate ~~topically active corticosteroid~~ is administered in combination with prednisone and prednisolone at 2 mg/kg.
9. (Currently amended) The method of claim 1 wherein the beclomethasone dipropionate ~~topically active corticosteroid~~ is formulated for oral administration in the form of a pill, capsule or microsphere.
10. (Currently amended) The method of claim 7 wherein the beclomethasone dipropionate ~~of topically active corticosteroid~~ is formulated such that the pill, microsphere, or capsule dissolves in the stomach, small intestine or colon.
11. (Currently amended) The method of claim 1 wherein the beclomethasone dipropionate ~~topically active corticosteroid~~

is formulated for oral administration in the form of an emulsion.

12. (Currently amended) The method of claim 1 wherein administration of the beclomethasone dipropionate ~~topically active corticosteroid~~ initiates following infusion of the hematopoietic cells.

13. (Currently amended) The method of claim 1 wherein administration of the beclomethasone dipropionate ~~topically active corticosteroids~~ ceases after 80 days following infusion of the hematopoietic cells.

14. (Previously presented) The method of claim 1 wherein the patient is the recipient of HLA-mismatched hematopoietic stem cells.

15. (Previously presented) The method of claim 1 wherein the patient is the recipient of unrelated donor hematopoietic stem cells, umbilical vein hematopoietic stem cells, or peripheral blood stem cells.

16. (Currently amended) The method of claim 1 wherein the beclomethasone dipropionate ~~topically active corticosteroid~~ is administered in combination with other prophylactic agents.

17.-18. (Canceled)